Soleno Therapeutics (SLNO) Change in Accured Expenses (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Change in Accured Expenses data on file, last reported at -$4.0 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$4.0 million, down 522.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $12000.0 (down 98.06% YoY), and the FY2025 annual result was $4.9 million, up 1453.87% from the prior year.
• Change in Accured Expenses fell to -$4.0 million in Q1 2026 per SLNO's latest filing, from $2.4 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $2.5 million in Q2 2025 and troughed at -$4.0 million in Q1 2026.
• A 5-year average of $176000.0 and a median of $144000.0 in 2022 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2023 and 2025: Change in Accured Expenses tumbled 1044.55% in 2023, then jumped 2225.0% in 2025.
• A 5-year view of Change in Accured Expenses shows it stood at $599000.0 in 2022, then soared by 99.33% to $1.2 million in 2023, then tumbled by 123.2% to -$277000.0 in 2024, then soared by 976.9% to $2.4 million in 2025, then tumbled by 262.78% to -$4.0 million in 2026.
• Business Quant data shows SLNO's Change in Accured Expenses at -$4.0 million in Q1 2026, $2.4 million in Q4 2025, and -$962000.0 in Q3 2025.